Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06169540 · ClinicalTrials.gov registry record
Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)
A clinical trial of Control and CHF, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT06169540: Recruiting study of Control and CHF, sponsored by Massachusetts General Hospital.
NCT06169540 is a study of Control and CHF that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 90 participants, below the 181-participant average among 5 other Control trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06169540, a study of Control and CHF, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Failure (CHF) to see if a new, non-invasive diagnostic test can be developed for heart failure exacerbation.
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-12-31 |
What NCT06169540 shows while recruiting
NCT06169540 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 181-participant average among 5 other Control trials with a reported enrollment target (50% lower).
The record links to 3 conditions, with Control appearing as the primary indexed condition, and to 0 interventions.
NCT06169540 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06169540 about?
NCT06169540 is a clinical study titled "Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)". The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Fai...
What is the current status of trial NCT06169540?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2023-04-19. Estimated completion is 2027-12-31.
What conditions does trial NCT06169540 study?
This clinical trial studies the following conditions: Control, CHF, ADHF.
Who is sponsoring clinical trial NCT06169540?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06169540 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Control
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Controlled Trial Testing the Effect of the Youth Mindful Awareness Program on Negative Affect (YMAP2).
RECRUITING · NA
-
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
RECRUITING
-
Coaching Teachers in Bullying Detection and Intervention
RECRUITING · NA
-
Neuroscience-Informed Treatment Development for Adolescent Alcohol Use
COMPLETED · Phase 2
-
Intervening With Children/Adolescents With FAS/ARND
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI